-
AI looms large ahead of Xi, Trump summit
-
Trump to host Xi amid pomp, low expectations
-
Smith still haunted by 'Sandpapergate' as he prepares for South Africa Tests
-
Harry set for UK public outings with security, royal status hazy
-
UK-Sudanese author pens book to give children 'African history of Africa'
-
NFL Chiefs' Kelce among investors bilked in Ponzi scheme
-
Boehly and Walter sell Chelsea stake to Clearlake Capital
-
Trump threatens EU over 'hostile' Canada association plan
-
US House backs data center power cost bill amid midterm backlash
-
Argentine judge orders suspension of Falklands oil project
-
US Congress passes sweeping Russia sanctions bill
-
Carrick takes the blame as troubled Man Utd suffer League Cup misery
-
Barca hit Racing for seven as Atletico crush Osasuna
-
Barcelona hit seven in Racing Santander rout
-
US Fed raises rates to tackle 'too high' inflation, irking Trump
-
Amorim's Milan beaten by Benfica, Sunderland make dream European return
-
Man Utd misery mounts after League Cup collapse against Brighton
-
US stocks fall, dollar gains after Fed lifts interest rates
-
Turkey releases 106 protesters, jails more LGBTQ activists
-
Seahawks rule out Darnold for Sunday game at Arizona
-
US Fed raises rates to tackle 'too high' inflation in move sure to rile Trump
-
Mbappe explains Ceuta shirt stance after criticism
-
England were 'waiting for death' in World Cup semi-final defeat: Tuchel
-
Improving Atletico cruise to comfortable win over Osasuna
-
NFL star fined for displaying name of slain Palestinian girl
-
Candidate for UN chief calls for AI regulation akin to nuclear weapons
-
Witsel retires from internationals after 18-year Belgium career
-
O'Neill expects Celtic recovery after Old Firm misery
-
US Fed raises rates to battle inflation in move likely to rile Trump
-
Man City midfield trio backed to emulate Rodri and Silva
-
Fitzpatrick 'not comfortable' over Dubai golf finale
-
'We're losing control,' AI pioneer Yoshua Bengio tells AFP
-
Gaza apartment block collapse kills 21, including 12 children
-
WHO eyes 'encouraging' signs in DRCongo fight against Ebola
-
Gaza apartment block collapse leaves 21 dead
-
Liga boss criticises Real Madrid trio for Ceuta shirt incident
-
US House targets data centers as midterm backlash grows
-
WTA Finals moved to Charlotte from 2027
-
French ex-minister Dati goes on trial in Renault-Nissan corruption case
-
Almost 8,000 excess deaths in France's scorched summer: statistics
-
'Being Heumann' captures joy in fight for disability rights
-
Ex-president's lengthy war crimes sentence shocks Kosovo
-
Retired great Nadal to play in exhibition matches
-
US House faces test on sweeping Russia sanctions bill
-
IR-MED and Dice Technologies Announce collaboration to Evaluate and Advance Pressure-Injury Prevention Platform in Japan
-
British PM says to make 'difficult decisions' as inflation rises
-
Watts, Pitt, Cruz to light up Spain's top film festival
-
TotalEnergies pumps up controversy in France with cut-price gas
-
Sweden expels Iran embassy employee over anti-Jewish threats
-
Global fuel price demos: a round-up
US drugmaker Eli Lilly says slashing insulin prices by 70%
US pharmaceutical giant Eli Lilly announced Wednesday it was cutting the cost of its most commonly prescribed insulins by 70 percent after years of soaring prices that hit millions of Americans living with diabetes.
The announcement comes as the cost of insulin has surged in recent years, with demand increasing significantly as well.
"Lilly is taking these actions to make it easier to access Lilly insulin and help Americans who may have difficulty navigating a complex healthcare system," the Indianapolis-based drugmaker said in a statement.
The company added it would cut the price of its non-branded insulin to $25 a vial starting May 1.
It will also lower the price of Humalog, its most commonly prescribed insulin, and Humulin, by 70 percent starting in the fourth quarter of this year.
"While the current healthcare system provides access to insulin for most people with diabetes, it still does not provide affordable insulin for everyone and that needs to change," said Lilly CEO David Ricks.
The company also said Wednesday it would automatically cap out-of-pocket costs at certain retail pharmacies at $35, for people with commercial insurance using Lilly insulin.
Diabetes is one of the fastest-growing chronic diseases globally, according to a 2022 study.
- Soaring prices -
In recent decades, insulin prices have soared in the United States, costing over eight times more than in 32 comparable high-income countries, a 2020 Rand Corporation study found.
But the cost of producing insulin is relatively low compared to the sale price.
A survey by nonprofit T1International also showed that one in four respondents living with diabetes reported rationing their insulin because of the financial strain.
In his State of the Union address last month, President Joe Biden said: "Big Pharma has been unfairly charging people hundreds of dollars –- and making record profits. Not anymore."
While seniors on Medicare have the cost of insulin capped, millions of other Americans not on the federal health insurance program for the elderly need insulin to save their lives, he added.
"Let's finish the job this time. Let's cap the cost of insulin at $35 a month for every American who needs it," Biden said.
Diabetes is divided into two types. An estimated nine million people have type 1 diabetes, a chronic condition where the pancreas does not produce enough insulin -- the hormone that regulates blood sugar levels.
Most people living with diabetes have type 2, which is associated with obesity and other lifestyle factors and emerges in adults and increasingly among children.
All type 1 diabetics need insulin to survive, and generally their access is ensured.
Some 63 million people with type 2 also need the hormone, according to World Health Organization estimates, but only about half of them can access it.
P.Smith--AT